Bezlotoxumab denied as non-formulary by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab as Non-Formulary

A non-formulary denial means bezlotoxumab is either absent from Aetna's current drug formulary or placed at a tier that your specific plan does not cover without an exception. Formulary placement decisions are made at the plan level and may not reflect clinical appropriateness for your individual situation. Non-formulary status alone does not mean the drug is inappropriate — it means it was not included in the negotiated drug list, often for cost or utilization-management reasons.

## Why This Denial Is Appealable

Virtually all ACA-compliant and ERISA plans provide a formulary-exception process for situations where a non-formulary drug is medically necessary and no formulary alternative is clinically appropriate for the individual patient. If your prescriber has determined that available formulary alternatives are contraindicated, have already failed, or are otherwise clinically inappropriate for your specific case, that determination is the foundation of a non-formulary exception appeal.

## Federal Appeal Framework

• Formulary exception request: This is typically the first step — a request (not yet a formal appeal) asking Aetna to cover a non-formulary drug based on medical necessity. It may resolve the issue without a formal appeal.
• Internal appeal (ERISA §503 / ACA): If the exception is denied, file a formal internal appeal within the deadline on your denial notice.
• External review (ACA §2719): If the internal appeal fails, an Independent Review Organization reviews the decision. The window is approximately four months from the final internal denial.
• Expedited option: Available with prescriber certification of urgent need.

## Concrete Appeal Steps

1. Request Aetna's formulary exception criteria for bezlotoxumab and the plan's complete formulary tier structure. 2. Identify every formulary alternative Aetna considers therapeutically equivalent for your condition. 3. Ask your prescriber to document — for each listed alternative — why it is not appropriate for your case (prior failure with dates, clinical contraindication per your chart, or other individualized reason). 4. Submit a formulary exception request first; if denied, escalate to formal internal appeal. 5. Attach the FDA-approved prescribing label (Zinplava) highlighting the indication and patient-population language.

## Documentation to Gather

• Diagnosis and prior treatment history: Laboratory confirmation of C. difficile infection, all prior treatment episodes with dates and outcomes.
• Formulary-alternative documentation: For each drug Aetna lists as an alternative, a chart note or prescriber statement explaining clinical unsuitability for this patient.
• Recurrence risk documentation: Any risk factors documented in the chart relevant to the FDA label's indicated population.
• Prescriber medical-necessity letter: Specifically addressing why bezlotoxumab — rather than a formulary alternative — is required for this patient.

## Criteria-Mapping Structure

Obtain Aetna's formulary exception policy and the published criteria for non-formulary approval. Map each criterion to a specific chart or prescriber document. For the alternative-drug analysis, use a row per alternative: (1) drug name, (2) reason it is not appropriate for this patient, (3) supporting chart citation. Completeness here is essential — a reviewer who can see that every alternative was considered and excluded individually has no residual basis for the denial.